DeepSeek addition to ClouDr medical AI platform drives share-price surge

Chinese company says DeepSeek’s AI model will enhance data mining in its platform, delivering efficiency to hospitals and pharmacies

Reading Time:2 minutes

ClouDr’s medical AI platform enables remote consultations and prescriptions. Photo: Shutterstock

Published: 12:34pm, 6 Feb 2025

Shares of Chinese digital healthcare company ClouDr Group surged for a second day after it announced that it has embedded DeepSeek’s artificial intelligence (AI) technology into its platform to deliver efficiency gains in hospital and pharmacy operations.

The integration of the DeepSeek R1 model into the medical AI platform ClouDr Brain would bolster the platform’s data-mining capabilities to boost clients’ efficiency in handling patients with chronic conditions, Kuang Ming, chairman and CEO, said in a statement to Hong Kong’s bourse on Thursday.

ClouDr shares rose as much as 27.3 per cent to a four-month high of HK$2.05 soon after the market opened on Thursday. On Wednesday, the stock jumped 26.8 per cent. ClouDr’s shares debuted at HK$30.50 when it went public in mid-2022.

Adoption of DeepSeek by Chinese companies is on the rise after the AI company emerged as China’s hottest tech start-up by stunning experts worldwide with the efficiency of its open-source large language models. The company said its V3 model, released on December 26, was trained in around two months at a cost of US$5.58 million, using significantly fewer computing resources than competing AI products.

“Following this integration and by leveraging [ClouDr’s] over 1 billion electronic health records, the company’s ClouD GPT and ClouD DTx models will achieve functional upgrades regarding the medical knowledge graph and the clinical decision-support system to optimise user experience and improve diagnostic efficiency,” ClouDr said.

Both ClouDr and DeepSeek are based in Hangzhou, in eastern China’s Zhejiang province.